This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.
Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2018.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion
by Zacks Equity Research
Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
by Zacks Equity Research
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Bristol-Myers' Sprycel Gets European Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Top Research Reports for Visa, Charter Communications & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Charter Communications (CHTR) and Biogen (BIIB).
Roche Submits sBLA to FDA for Label Expansion of Kadcyla
by Zacks Equity Research
Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.
Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance
by Zacks Equity Research
Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.